Voronoi to strengthen AI-driven open innovation

It plans to enhance profitability and expand research scope by securing pipeline via new drug development platform

Voronoi to strengthen AI-driven open innovation
Yoo-Rim Kim 1
2023-08-28 18:19:58 youforest@hankyung.com
Bio & Pharma

South Korea’s biotechnology startup Voronoi Inc. announced on Monday that it is intensifying its artificial intelligence (AI)-driven new drug development open innovation business.

The company filed a patent related to AI technology for lead optimization in its pipeline.

"Collaborative research companies can swiftly identify candidate substances with high selectivity and blood-brain barrier penetration using the Voronoi AI platform," said Kim Hyun-Tae, the head of Voronoi's management division. "Through open innovation, Voronoi aims to secure pipeline shares for increased profitability while expanding its research scope."

Voronoi is launching a new business of expanding its pipeline through AI-driven new drug development and open innovation with global pharmaceutical companies. The multidimensional validation of its AI new drug development platform, which has been refined using the largest experimental dataset in South Korea from the early stages of its founding, has been recently completed.

Through the synthesis of over 4,000 substances per year and animal experiments, Voronoi has amassed millions of experimental data points. It has also simultaneously pursued patent applications for substances at a level comparable to the top ten in the world in the same field.

Building on this foundation, it has developed the platform called Voronomix, which integrates AI into every aspect of the new drug development process, including substance discovery, patent assessment, synthesis feasibility analysis, drug efficacy improvement diagnosis and candidate substance optimization.

Write to Yoo-Rim Kim at youforest@hankyung.com
#Voronoi #AI-driven new drug development #open innovation #blood-brain barrier #new drug development platform #candidate substance optimization

Biotech startup Voronoi withdraws IPO plans

Biotech startup Voronoi withdraws IPO plans

Voronoi Inc. logo South Korea’s biotechnology startup Voronoi Inc. scrapped its plan to go public this month. The new drug developer announced Wednesday it had submitted a delisting notice to the Financial Supervisory Service, hit by lackluster investor confidence. The decision

Korea’s Voronoi in talks with global firms on drug designs

Korea’s Voronoi in talks with global firms on drug designs

Voronoi CEO Kim Dae-kwon South Korea’s biotechnology startup Voronoi Inc. is in talks with global biomedical companies on drug designs as it aims to expand the business and significantly improve earnings, its chief executive said.Voronoi, founded in 2015, is a company specialized in drug

Korea’s biotech startup Voronoi to go public in March

Korea’s biotech startup Voronoi to go public in March

(Courtesy of Voronoi) South Korea’s biotechnology startup Voronoi Inc. plans an initial public offering in March to raise up to 130 billion won ($108.4 million).Voronoi on Monday filed a registration statement to list new shares on the country’s junior Kosdaq. The new drug developer

Korea’s bio startup Voronoi inks $324 million deal with Brickell Biotech

Korea’s bio startup Voronoi inks $324 million deal with Brickell Biotech

Biotechnology is one of the fastest-growing sectors Voronoi Inc., a South Korean biotechnology startup, has clinched a $324 million deal to grant Brickell Biotech, a US clinical-stage pharmaceutical firm, access to a platform of inhibitors targeting neuroinflammatory and other autoimmune diseas
(* comment hide *}